Premium
Confirmatory molecular method for HTLV‐1/2 infection in high‐risk pregnant women
Author(s) -
Medeiros Ana C. M.,
Vidal Luine R. R.,
Von Linsingen Renate,
Ferin Aline N.,
Bessani Strapasson Talita,
de Almeida Sergio M.,
Raboni Sonia M.,
Carvalho Newton S.,
Bordig Nogueira Meri
Publication year - 2018
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25014
Subject(s) - medicine , breastfeeding , serology , transmission (telecommunications) , obstetrics , pregnancy , sexual intercourse , virology , prenatal care , immunology , antibody , pediatrics , biology , population , environmental health , electrical engineering , genetics , engineering
Human T‐cell lymphotropic virus types 1/2 (HTLV‐1/2) are transmitted through sexual intercourse, transfusion of blood components, and vertical transmission, predominantly through breastfeeding. Six hundred forty‐three pregnant women from a high‐risk prenatal care unit at a general hospital were tested by serological tests using chemiluminescence (CMIA) for screening, followed by a molecular confirmatory test. Four patients (0.6%) tested positive for HTLV‐1/2 by CMIA, two samples (0.3%) for each patient were confirmed as having HTLV‐1 or HTLV‐2 by PCR. The results show the importance of inclusion of HTLV‐1/2 screening for pregnant women in high‐risk prenatal care and the need for a molecular biological method to confirm HTLV‐1/2 infection.